Wells Fargo & Company Fulcrum Therapeutics, Inc. Transaction History

Wells Fargo & Company

$433 Billion
Q4 2024

A detailed history of Wells Fargo & Company transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 34,264 shares of FULC stock, worth $126,434. This represents 0.0% of its overall portfolio holdings.

Number of Shares

34,264

Previous 25,503 34.35%

Holding current value

$126,434

Previous $91,000 76.92%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 12, 2025	BUY	$2.97 - $4.84 $26,020 - $42,403	8,761 Added 34.35%	34,264 $161,000
Q3 2024 Nov 13, 2024	BUY	$3.18 - $9.74 $1,217 - $3,730	383 Added 1.52%	25,503 $91,000
Q2 2024 Aug 13, 2024	BUY	$5.98 - $9.31 $147,903 - $230,264	24,733 Added 6390.96%	25,120 $155,000
Q1 2024 May 10, 2024	BUY	$6.7 - $12.0 $40 - $72	6 Added 1.57%	387 $3,000
Q4 2023 Feb 09, 2024	BUY	$3.18 - $6.86 $63 - $137	20 Added 5.54%	381 $2,000
Q3 2023 Nov 13, 2023	SELL	$3.25 - $6.08 $1,963 - $3,672	-604 Reduced 62.59%	361 $1,000
Q2 2023 Aug 15, 2023	SELL	$2.26 - $3.8 $19,890 - $33,443	-8,801 Reduced 90.12%	965 $3,000
Q1 2023 May 12, 2023	BUY	$2.83 - $13.99 $18,595 - $91,928	6,571 Added 205.67%	9,766 $27,000
Q4 2022 Feb 13, 2023	SELL	$5.01 - $8.35 $11,813 - $19,689	-2,358 Reduced 42.46%	3,195 $23,000
Q3 2022 Nov 14, 2022	SELL	$4.92 - $9.1 $1,559 - $2,884	-317 Reduced 5.4%	5,553 $45,000
Q2 2022 Aug 12, 2022	SELL	$4.2 - $24.0 $34,368 - $196,392	-8,183 Reduced 58.23%	5,870 $29,000
Q1 2022 May 16, 2022	SELL	$9.96 - $23.65 $87,299 - $207,292	-8,765 Reduced 38.41%	14,053 $332,000
Q4 2021 Feb 14, 2022	BUY	$14.0 - $28.44 $237,426 - $482,313	16,959 Added 289.45%	22,818 $403,000
Q3 2021 Nov 15, 2021	SELL	$7.28 - $30.97 $15,091 - $64,200	-2,073 Reduced 26.13%	5,859 $165,000
Q2 2021 Aug 16, 2021	SELL	$8.09 - $12.0 $11,463 - $17,004	-1,417 Reduced 15.16%	7,932 $83,000
Q1 2021 May 13, 2021	SELL	$10.94 - $15.32 $103,744 - $145,279	-9,483 Reduced 50.36%	9,349 $110,000
Q4 2020 Feb 09, 2021	BUY	$7.84 - $13.4 $31,297 - $53,492	3,992 Added 26.9%	18,832 $221,000
Q3 2020 Nov 05, 2020	SELL	$7.22 - $20.7 $3,306 - $9,480	-458 Reduced 2.99%	14,840 $117,000
Q2 2020 Aug 13, 2020	BUY	$9.11 - $22.06 $56,263 - $136,242	6,176 Added 67.7%	15,298 $279,000
Q1 2020 May 14, 2020	BUY	$9.49 - $21.26 $86,567 - $193,933	9,122 New	9,122 $109,000

Others Institutions Holding FULC

# of Institutions

134

Shares Held

52.8M

Call Options Held

3.08M

Put Options Held

316K

View Full List

About Fulcrum Therapeutics, Inc.

Ticker FULC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,038,900
Market Cap $192M
Description
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...

More about FULC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Fulcrum Therapeutics, Inc. Transaction History